The Long Tail of Oncogenic Drivers in Prostate Cancer

Comprehensive genomic characterization of prostate cancer has identified recurrent alterations in genes involved in androgen signaling, DNA repair, and PI3K signaling, among others. However, larger and uniform genomic analysis may identify additional recurrently mutated genes at lower frequencies. Here we aggregate and uniformly analyze exome sequencing data from 1,013 prostate cancers. We identify and validate a new class of E26 transformation-specific (ETS)-fusion-negative tumors defined by mutations in epigenetic regulators, as well as alterations in pathways not previously implicated in prostate cancer, such as the spliceosome pathway. We find that the incidence of significantly mutated genes (SMGs) follows a long-tail distribution, with many genes mutated in less than 3% of cases. We identify a total of 97 SMGs, including 70 not previously implicated in prostate cancer, such as the ubiquitin ligase CUL3 and the transcription factor SPEN. Finally, comparing primary and metastatic prostate cancer identifies a set of genomic markers that may inform risk stratification.

Citing Articles

The Landscape of PARP Inhibitors in Solid Cancers.

Muzzana M, Broggini M, Damia G Onco Targets Ther. 2025; 18:297-317.

PMID: 40051775 PMC: 11884256. DOI: 10.2147/OTT.S499226.

Unveiling Racial Disparities in Localized Prostate Cancer: A Systems-Level Exploration of the lncRNA Landscape.

Morgan R, Hazard E, Savage S, Halbert C, Gattoni-Celli S, Hardiman G Genes (Basel). 2025; 16(2).

PMID: 40004558 PMC: 11855151. DOI: 10.3390/genes16020229.

The Landscape of Prostate Tumour Methylation.

Arbet J, Yamaguchi T, Shiah Y, Hugh-White R, Wiggins A, Oh J bioRxiv. 2025; .

PMID: 39990314 PMC: 11844408. DOI: 10.1101/2025.02.07.637178.

Distinct outcomes from targeted perturbations of the multi-subunit SCF E3 ubiquitin ligase in blocking Trp53/Rb1-null prostate tumorigenesis.

Xue Y, Zhu L, Karan S, Locker J, Branch C, Zhang J Commun Biol. 2025; 8(1):278.

PMID: 39987265 PMC: 11846996. DOI: 10.1038/s42003-025-07662-3.

A Novel Molecular Profile of Hormone-Sensitive Prostate Cancer Defines High Risk Patients.

Piombino C, Nasso C, Bettelli S, Manfredini S, Vitale M, Pipitone S Cancer Med. 2025; 14(4):e70472.

PMID: 39980141 PMC: 11842281. DOI: 10.1002/cam4.70472.

References

Kumar A, Coleman I, Morrissey C, Zhang X, True L, Gulati R . Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med. 2016; 22(4):369-78. PMC: 5045679. DOI: 10.1038/nm.4053. View

Cibulskis K, Lawrence M, Carter S, Sivachenko A, Jaffe D, Sougnez C . Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013; 31(3):213-9. PMC: 3833702. DOI: 10.1038/nbt.2514. View

McHugh C, Chen C, Chow A, Surka C, Tran C, McDonel P . The Xist lncRNA interacts directly with SHARP to silence transcription through HDAC3. Nature. 2015; 521(7551):232-6. PMC: 4516396. DOI: 10.1038/nature14443. View

Van Allen E, Wagle N, Stojanov P, Perrin D, Cibulskis K, Marlow S . Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med. 2014; 20(6):682-8. PMC: 4048335. DOI: 10.1038/nm.3559. View

Lawrence M, Stojanov P, Mermel C, Robinson J, Garraway L, Golub T . Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014; 505(7484):495-501. PMC: 4048962. DOI: 10.1038/nature12912. View

Lek M, Karczewski K, Minikel E, Samocha K, Banks E, Fennell T . Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016; 536(7616):285-91. PMC: 5018207. DOI: 10.1038/nature19057. View

Hartmaier R, Albacker L, Chmielecki J, Bailey M, He J, Goldberg M . High-Throughput Genomic Profiling of Adult Solid Tumors Reveals Novel Insights into Cancer Pathogenesis. Cancer Res. 2017; 77(9):2464-2475. DOI: 10.1158/0008-5472.CAN-16-2479. View

Costello M, Pugh T, Fennell T, Stewart C, Lichtenstein L, Meldrim J . Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation. Nucleic Acids Res. 2013; 41(6):e67. PMC: 3616734. DOI: 10.1093/nar/gks1443. View

Cibulskis K, McKenna A, Fennell T, Banks E, DePristo M, Getz G . ContEst: estimating cross-contamination of human samples in next-generation sequencing data. Bioinformatics. 2011; 27(18):2601-2. PMC: 3167057. DOI: 10.1093/bioinformatics/btr446. View

10.

Tomlins S, Rhodes D, Perner S, Dhanasekaran S, Mehra R, Sun X . Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005; 310(5748):644-8. DOI: 10.1126/science.1117679. View

11.

Hieronymus H, Schultz N, Gopalan A, Carver B, Chang M, Xiao Y . Copy number alteration burden predicts prostate cancer relapse. Proc Natl Acad Sci U S A. 2014; 111(30):11139-44. PMC: 4121784. DOI: 10.1073/pnas.1411446111. View

12.

Saunders C, Wong W, Swamy S, Becq J, Murray L, Cheetham R . Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics. 2012; 28(14):1811-7. DOI: 10.1093/bioinformatics/bts271. View

13.

Robinson D, Van Allen E, Wu Y, Schultz N, Lonigro R, Mosquera J . Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 161(5):1215-1228. PMC: 4484602. DOI: 10.1016/j.cell.2015.05.001. View

14.

Lawrence M, Stojanov P, Polak P, Kryukov G, Cibulskis K, Sivachenko A . Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-218. PMC: 3919509. DOI: 10.1038/nature12213. View

15.

Shen R, Seshan V . FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 2016; 44(16):e131. PMC: 5027494. DOI: 10.1093/nar/gkw520. View

16.

Legare S, Cavallone L, Mamo A, Chabot C, Sirois I, Magliocco A . The Estrogen Receptor Cofactor SPEN Functions as a Tumor Suppressor and Candidate Biomarker of Drug Responsiveness in Hormone-Dependent Breast Cancers. Cancer Res. 2015; 75(20):4351-63. DOI: 10.1158/0008-5472.CAN-14-3475. View

17.

Fraser M, Sabelnykova V, Yamaguchi T, Heisler L, Livingstone J, Huang V . Genomic hallmarks of localized, non-indolent prostate cancer. Nature. 2017; 541(7637):359-364. DOI: 10.1038/nature20788. View

18.

Geng C, He B, Xu L, Barbieri C, Eedunuri V, Chew S . Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proc Natl Acad Sci U S A. 2013; 110(17):6997-7002. PMC: 3637757. DOI: 10.1073/pnas.1304502110. View

19.

Yuan W, Lee Y, Huang S, Lin Y, Chen T, Chung H . A Cullin3-KLHL20 Ubiquitin ligase-dependent pathway targets PML to potentiate HIF-1 signaling and prostate cancer progression. Cancer Cell. 2011; 20(2):214-28. DOI: 10.1016/j.ccr.2011.07.008. View

20.

Mermel C, Schumacher S, Hill B, Meyerson M, Beroukhim R, Getz G . GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011; 12(4):R41. PMC: 3218867. DOI: 10.1186/gb-2011-12-4-r41. View